A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of
a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison …

ABSTRACT Background: In the United States (US), diphtheria, tetanus, and acellular
pertussis (DTaP) vaccination is recommended at 2, 4, and 6 months (doses 1–3), 15–18 …

Objective To evaluate the effectiveness and safety of DTaP-IPV/Hib combined vaccine in
comparison with commercially available DTaP (diphtheria, tetanus and pertussis) …

Objective To examine the impact of a minimum interval schedule for administering
diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) in infants during a …

Persistence of antibodies after a single dose of Tdap vaccine (tetanus, diphtheria, and 5-
component acellular pertussis vaccine) was evaluated in a follow-up study of adolescents …

Background: During the decade 1998-2007, a combination DTaP 5-IPV/Hib vaccine was
used exclusively in Canada to immunize infants and young children against diphtheria …

ABSTRACT Background: An acellular Pertussis (aP) vaccine containing recombinant
genetically detoxified Pertussis Toxin (PTgen), Filamentous Hemagglutinin (FHA) and …

Abstract▴ The reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine
(dTpa) is intended for use as a booster dose in individuals aged≥ 4 years.▴ A single dose …

Background Acellular pertussis vaccines were initially licensed based on placebo-controlled
efficacy trials, but such trials are no longer ethical. The effectiveness of current pertussis …

The Advisory Committee on Immunization Practices recommends administering diphtheria,
tetanus and acellular pertussis (DTaP) vaccines to children at 2, 4, 6, 15–18 months, and 4 …